A number of potential therapies are in development for treatment of genetic neuromuscular diseases. These diseases include Duchenne muscular dystrophy (DMD) and spinal muscular atrophy (SMA) type 3. Subjects with these diseases present initially with proximal lower limb weakness that leads to progressive difficulties in ambulation. The final step in translational research is the demonstration of efficacy of a potential treatment or approach in a clinical trial. Specific, quantifiable, objective, and reliable measures are required. The importance of such measures was recently emphasized by the failure of the phase IIb ataluren trial1 and the phase III Biomarin trial2. One of the likely explanations for these failures was the variability and the nonlinear evolution of the primary outcome measure of these trials, the 6-minute walk test3 (6 MWT). Increasing reliability and sensitivity to the change of outcome measures and the understanding of the factors leading to their variation could contribute to decrease the number of trial failures related to the main outcome measures.
One of the limitations of the current outcomes is the subjectivity of the assessment. To further increase the objectivity of assessments, Heberer et al.4 showed that through a marker set and the use of a gait analysis software, there was a significant increase in stride length in patients treated with steroids compared with the naïve group. Hip joint kinetics are early markers of proximal weakness in patients with DMD and are responsive to change with steroid intervention, which is the only available treatment for these patients. Gait laboratories are, however, only available in large clinics. Furthermore, laboratory evaluations are point assessments, and a patient’s condition may greatly vary on a day to day basis due to factors such as fatigue, motivation, and intercurrent illness.
The use of continuous and home-based measurement should achieve both a more objective and a more globally representative assessment. In other fields of neurology, for instance Parkinson5 or multiple sclerosis6, several studies have assessed the feasibility, reliability, and consistency with other measures of different sensors including accelerometers with or without gyrometers or magnetometers, yet none of these devices is currently a gold standard for evaluation of patients during clinical trials. In the field of neuromuscular diseases, there is currently no validated method for continuous home monitoring of patients. In recent years, through a close collaboration between clinicians and engineers, the Institute of Myology in Paris has developed several devices for upper limb assessment to precisely evaluate upper limb strength and function7,8,9. A wearable magneto-inertial sensor (WMIS; i.e., ActiMyo) has been developed in collaboration with a company specialized in navigation systems. Initially a monitoring device dedicated to non-ambulant subjects with neuromuscular disorders such as DMD and SMA10,11, the same device has now been used to monitor ambulant patients in two different configurations: sensors on both ankles or one sensor at the wrist and the other one at the ankle. The configuration for a non-ambulant population is composed of a sensor at the wheelchair and the other one at the wrist.
This WMIS is able to precisely capture and quantify all movements of the limb on which it is placed. The measuring principle is based on the use of microelectromechanical system (MEMS) inertial sensors and magnetometers operated through magneto-inertial equations. Dedicated algorithms allow precise qualification and quantification of patients’ movements in a non-controlled environment.
The overall goal of the method is to provide identification and quantification of any movement produced by a patient over a pre-defined period of time, and to integrate these measures into disease-specific outcome measures representative of the patient’s condition over a period of time.
To effectively assess ambulant and non-ambulant patients with movement disorders at home, the device must be provided to the patient by a trained evaluator who is responsible for making sure that the instructions have been understood. An investigator and a patient manual are provided with the device. This WMIS is currently being used as an exploratory outcome measure in a number of clinical trials for neuromuscular and neurologic diseases (NCT03351270, NCT02780492, NCT01385917, NCT03039686, NCT03368742, NCT02500381). Specific procedures adapted to the pathology and/or to the clinical trial design have been developed.